Abela AR, Browne CJ, Sargin D, et al., 2020. Median raphe serotonin neurons promote anxiety-like behavior via inputs to the dorsal hippocampus. Neuropharmacology, 168:107985. https://doi.org/10.1016/j.neuropharm.2020.107985https://doi.org/10.1016/j.neuropharm.2020.107985

al Kury LT, Mahgoub M, Howarth FC, et al., 2018. Natural negative allosteric modulators of 5-HT3 receptors. Molecules, 23(12):3186. https://doi.org/10.3390/molecules23123186https://doi.org/10.3390/molecules23123186

Alves SH, Pinheiro G, Motta V, et al., 2004. Anxiogenic effects in the rat elevated plus-maze of 5-HT2C agonists into ventral but not dorsal hippocampus. Behav Pharmacol, 15(1):37-43. https://doi.org/10.1097/00008877-200402000-00005https://doi.org/10.1097/00008877-200402000-00005

Andrade TGCS, Macedo CEA, Zangrossi H, et al., 2004. Anxiolytic-like effects of median raphe nucleus lesion in the elevated T-maze. Behav Brain Res, 153(1):55-60. https://doi.org/10.1016/j.bbr.2003.10.036https://doi.org/10.1016/j.bbr.2003.10.036

Artaiz I, Romero G, Zazpe A, et al., 1995. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology, 117(2):137-148. https://doi.org/10.1007/bf02245179https://doi.org/10.1007/bf02245179

Askari N, Moin M, Sanati M, et al., 2012. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs, 26(10):883-892. https://doi.org/10.2165/11635850-000000000-00000https://doi.org/10.2165/11635850-000000000-00000

Babaev O, Piletti Chatain C, Krueger-Burg D, 2018. Inhibition in the amygdala anxiety circuitry. Exp Mol Med, 50(4):1-16. https://doi.org/10.1038/s12276-018-0063-8https://doi.org/10.1038/s12276-018-0063-8

Bannerman DM, Matthews P, Deacon RM, et al., 2004. Medial septal lesions mimic effects of both selective dorsal and ventral hippocampal lesions. Behav Neurosci, 118(5):1033-1041. https://doi.org/10.1037/0735-7044.118.5.1033https://doi.org/10.1037/0735-7044.118.5.1033

Barnes JM, Barnes NM, Costall B, et al., 1990. Identification and distribution of 5-HT3 recognition sites within the human brainstem. Neurosci Lett, 111(1-2):80-86. https://doi.org/10.1016/0304-3940(90)90348-dhttps://doi.org/10.1016/0304-3940(90)90348-d

Barnes NM, Hales TG, Lummis SCR, et al., 2009. The 5-HT3 receptor ‍– the relationship between structure and function. Neuropharmacology, 56(1):273-284. https://doi.org/10.1016/j.neuropharm.2008.08.003https://doi.org/10.1016/j.neuropharm.2008.08.003

Basak S, Gicheru Y, Samanta A, et al., 2018. Cryo-EM structure of 5-HT3A receptor in its resting conformation. Nat Commun, 9:514. https://doi.org/10.1038/s41467-018-02997-4https://doi.org/10.1038/s41467-018-02997-4

Bhatnagar S, Nowak N, Babich L, et al., 2004. Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests. Behav Brain Res, 153(2):527-535. https://doi.org/10.1016/j.bbr.2004.01.018https://doi.org/10.1016/j.bbr.2004.01.018

Bhatt S, Mahesh R, Devadoss T, et al., 2013. Anxiolytic-like effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in experimental mouse models of anxiety. Indian J Pharmacol, 45(3):248-251. https://doi.org/10.4103/0253-7613.111923https://doi.org/10.4103/0253-7613.111923

Bhatt S, Mahesh R, Jindal A, et al., 2017a. Neuropharmacological and neurochemical evaluation of N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant- and anxiolytic-like potential using traumatic brain injury model in rats. J Basic Clin Physiol Pharmacol, 28(2):93-100. https://doi.org/10.1515/jbcpp-2016-0057https://doi.org/10.1515/jbcpp-2016-0057

Bhatt S, Mahesh R, Devadoss T, et al., 2017b. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice. J Basic Clin Physiol Pharmacol, 28(2):101-106. https://doi.org/10.1515/jbcpp-2016-0083https://doi.org/10.1515/jbcpp-2016-0083

Bhatt S, Devadoss T, Manjula SN, et al., 2021. 5-HT3 receptor antagonism: a potential therapeutic approach for the treatment of depression and other disorders. Curr Neuropharmacol, 19(9):1545-1559. https://doi.org/10.2174/1570159x18666201015155816https://doi.org/10.2174/1570159x18666201015155816

Bi WK, Luan SS, Wang J, et al., 2020. FSH signaling is involved in affective disorders. Biochem Biophys Res Commun, 525(4):915-920. https://doi.org/10.1016/j.bbrc.2020.03.039https://doi.org/10.1016/j.bbrc.2020.03.039

Birbaumer N, Grodd W, Diedrich O, et al., 1998. fMRI reveals amygdala activation to human faces in social phobics. NeuroReport, 9(6):1223-1226. https://doi.org/10.1097/00001756-199804200-00048https://doi.org/10.1097/00001756-199804200-00048

Bremner JD, Randall P, Scott TM, et al., 1995. MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry, 152(7):973-981. https://doi.org/10.1176/ajp.152.7.973https://doi.org/10.1176/ajp.152.7.973

Bremner JD, Hoffman M, Afzal N, et al., 2021. The environment contributes more than genetics to smaller hippocampal volume in Posttraumatic Stress Disorder (PTSD). J Psychiatr Res, 137:579-588. https://doi.org/10.1016/j.jpsychires.2020.10.042https://doi.org/10.1016/j.jpsychires.2020.10.042

Campbell AD, Womer DE, Simon JR, 1995. The 5-HT3 receptor agonist 1-‍(m-chlorophenyl)‍-biguanide interacts with the dopamine transporter in rat brain synaptosomes. Eur J Pharmacol: Mol Pharmacol, 290(2):157-162. https://doi.org/10.1016/0922-4106(95)90029-2https://doi.org/10.1016/0922-4106(95)90029-2

Celli J, Rappold G, Niesler B, 2017. The human serotonin type 3 receptor gene (HTR3A-E) allelic variant database. Hum Mutat, 38(2):137-147. https://doi.org/10.1002/humu.23136https://doi.org/10.1002/humu.23136

Challis C, Beck SG, Berton O, 2014. Optogenetic modulation of descending prefrontocortical inputs to the dorsal raphe bidirectionally bias socioaffective choices after social defeat. Front Behav Neurosci, 8:43. https://doi.org/10.3389/fnbeh.2014.00043https://doi.org/10.3389/fnbeh.2014.00043

Choi IS, Cho JH, Kim JT, et al., 2007. Serotoninergic modulation of GABAergic synaptic transmission in developing rat CA3 pyramidal neurons. J Neurochem, 103(6):‍2342-2353. https://doi.org/10.1111/j.1471-4159.2007.04945.xhttps://doi.org/10.1111/j.1471-4159.2007.04945.x

Cortes-Altamirano JL, Olmos-Hernandez A, Jaime HB, et al., 2018. Review: 5-HT1, 5-HT2, 5-HT3 and 5-HT7 receptors and their role in the modulation of pain response in the central nervous system. Curr Neuropharmacol, 16(2):210-221. https://doi.org/10.2174/1570159x15666170911121027https://doi.org/10.2174/1570159x15666170911121027

Costall B, Kelly ME, Naylor RJ, et al., 1989. Neuroanatomical sites of action of 5-HT3 receptor agonist and antagonists for alteration of aversive behaviour in the mouse. Br J Pharmacol, 96(2):325-332. https://doi.org/10.1111/j.1476-5381.1989.tb11821.xhttps://doi.org/10.1111/j.1476-5381.1989.tb11821.x

Crocq MA, 2015. A history of anxiety: from hippocrates to DSM. Dialogues Clin Neurosci, 17(3):319-325. https://doi.org/10.31887/DCNS.2015.17.3/macrocqhttps://doi.org/10.31887/DCNS.2015.17.3/macrocq

Cutler MG, 1991. An ethological study of the effects of buspirone and the 5-HT3 receptor antagonist, BRL 43694 (granisetron) on behaviour during social interactions in female and male mice. Neuropharmacology, 30(4):299-306. https://doi.org/10.1016/0028-3908(91)90053-ehttps://doi.org/10.1016/0028-3908(91)90053-e

de la Mora MP, Hernández-Gómez AM, Arizmendi-García Y, et al., 2007. Role of the amygdaloid cholecystokinin (CCK)/gastrin-2 receptors and terminal networks in the modulation of anxiety in the rat. Effects of CCK-4 and CCK-8S on anxiety-like behaviour and [3H]GABA release. Eur J Neurosci, 26(12):3614-3630. https://doi.org/10.1111/j.1460-9568.2007.05963.xhttps://doi.org/10.1111/j.1460-9568.2007.05963.x

del Boca C, Lutz PE, le Merrer J, et al., 2012. Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice. Neuroscience, 218:185-195. https://doi.org/10.1016/j.neuroscience.2012.05.022https://doi.org/10.1016/j.neuroscience.2012.05.022

el Nebrisi E, Prytkova T, Lorke DE, et al., 2020. Capsaicin is a negative allosteric modulator of the 5-HT3 receptor. Front Pharmacol, 11:1274. https://doi.org/10.3389/fphar.2020.01274https://doi.org/10.3389/fphar.2020.01274

Engin E, Treit D, 2007. The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol, 18(5-6):365-374. https://doi.org/10.1097/FBP.0b013e3282de7929https://doi.org/10.1097/FBP.0b013e3282de7929

Fawley JA, Doyle MW, Andresen MC, 2019. 5-HT3R-sourced calcium enhances glutamate release from a distinct vesicle pool. Brain Res, 1721:146346. https://doi.org/10.1016/j.brainres.2019.146346https://doi.org/10.1016/j.brainres.2019.146346

Gasiorek A, Trattnig SM, Ahring PK, et al., 2016. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors. Biochem Pharmacol, 110-111:92-108. https://doi.org/10.1016/j.bcp.2016.04.004https://doi.org/10.1016/j.bcp.2016.04.004

Giacobbe P, Flint A, 2018. Diagnosis and management of anxiety disorders. Continuum (Minneap Minn), 24(3):893-919. https://doi.org/10.1212/con.0000000000000607https://doi.org/10.1212/con.0000000000000607

Gibbs E, Chakrapani S, 2021. Structure, function and physiology of 5-hydroxytryptamine receptors subtype 3. In: Harris JR, Marles-Wright J (Eds.), Macromolecular Protein Complexes III: Structure and Function. Springer, Cham, p.373-408. https://doi.org/10.1007/978-3-030-58971-4_11https://doi.org/10.1007/978-3-030-58971-4_11

Giordano J, Gerstmann H, 2004. Patterns of serotonin- and 2-methylserotonin-induced pain may reflect 5-HT3 receptor sensitization. Eur J Pharmacol, 483(2-3):267-269. https://doi.org/10.1016/j.ejphar.2003.10.044https://doi.org/10.1016/j.ejphar.2003.10.044

Griffiths JL, Lovick TA, 2002. Co-localization of 5-HT2A-receptor- and GABA-immunoreactivity in neurones in the periaqueductal grey matter of the rat. Neurosci Lett, 326(3):151-154. https://doi.org/10.1016/s0304-3940(02)00182-9https://doi.org/10.1016/s0304-3940(02)00182-9

Gui ZH, Zhang QJ, Liu J, et al., 2010. In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT3 receptors in 6-hydroxydopamine-induced Parkinsonian rats. Neuroscience, 169(3):1315-1325. https://doi.org/10.1016/j.neuroscience.2010.05.059https://doi.org/10.1016/j.neuroscience.2010.05.059

Gupta D, Thangaraj D, Radhakrishnan M, 2016. A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: modulation of serotonergic system. Behav Brain Res, 297:41-50. https://doi.org/10.1016/j.bbr.2015.10.007https://doi.org/10.1016/j.bbr.2015.10.007

Harmer CJ, Reid CB, Ray MK, et al., 2006. 5HT3 antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology, 186:18-24. https://doi.org/10.1007/s00213-006-0337-zhttps://doi.org/10.1007/s00213-006-0337-z

Harrell AV, Allan AM, 2003. Improvements in hippocampal-dependent learning and decremental attention in 5-HT3 receptor overexpressing mice. Learn Mem, 10(5):410-419. https://doi.org/10.1101/lm.56103https://doi.org/10.1101/lm.56103

Haus U, Varga B, Stratz T, et al., 2000. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol, 29(113):55-58. https://doi.org/10.1080/030097400446652https://doi.org/10.1080/030097400446652

Hensler JG, Hodge CW, Overstreet DH, 2004. Reduced 5-HT3 receptor binding and lower baseline plus maze anxiety in the alcohol-preferring inbred fawn-hooded rat. Pharmacol Biochem Behav, 77(2):281-289. https://doi.org/10.1016/j.pbb.2003.11.015https://doi.org/10.1016/j.pbb.2003.11.015

Hewlett WA, Schmid SP, Salomon RM, 2003. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry, 64(9):1025-1030. https://doi.org/10.4088/jcp.v64n0907https://doi.org/10.4088/jcp.v64n0907

Higgins GA, Jones BJ, Oakley NR, et al., 1991. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology, 104(4):545-551. https://doi.org/10.1007/bf02245664https://doi.org/10.1007/bf02245664

Holm L, Liang W, Thorsell A, et al., 2014. Acute effects on brain cholecystokinin-like concentration and anxiety-like behaviour in the female rat upon a single injection of 17β‍-estradiol. Pharmacol Biochem Behav, 122:222-227. https://doi.org/10.1016/j.pbb.2014.04.004https://doi.org/10.1016/j.pbb.2014.04.004

Hutchison SM, Mâsse LC, Pawluski JL, et al., 2021. Perinatal selective serotonin reuptake inhibitor (SSRI) and other antidepressant exposure effects on anxiety and depressive behaviors in offspring: a review of findings in humans and rodent models. Reprod Toxicol, 99:80-95. https://doi.org/10.1016/j.reprotox.2020.11.013https://doi.org/10.1016/j.reprotox.2020.11.013

Irving H, Turek I, Kettle C, et al., 2021. Tapping into 5-HT3 receptors to modify metabolic and immune responses. Int J Mol Sci, 22(21):11910. https://doi.org/10.3390/ijms222111910https://doi.org/10.3390/ijms222111910

Juza R, Vlcek P, Mezeiova E, et al., 2020. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev, 40(5):1593-1678. https://doi.org/10.1002/med.21666https://doi.org/10.1002/med.21666

Kilpatrick GJ, Jones BJ, Tyers MB, 1987. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature, 330(6150):746-748. https://doi.org/10.1038/330746a0https://doi.org/10.1038/330746a0

Kilpatrick GJ, Butler A, Burridge J, et al., 1990. 1-‍(m-Chlorophenyl)‍-biguanide, a potent high affinity 5-HT3 receptor agonist. Eur J Pharmacol, 182(1):193-197. https://doi.org/10.1016/0014-2999(90)90513-6https://doi.org/10.1016/0014-2999(90)90513-6

Koch SBJ, van Zuiden M, Nawijn L, et al., 2017. Decreased uncinate fasciculus tract integrity in male and female patients with PTSD: a diffusion tensor imaging study. J Psychiatry Neurosci, 42(5):331-342. https://doi.org/10.1503/jpn.160129https://doi.org/10.1503/jpn.160129

Koyama Y, Kondo M, Shimada S, 2017. Building a 5-HT3A receptor expression map in the mouse brain. Sci Rep, 7:42884. https://doi.org/10.1038/srep42884https://doi.org/10.1038/srep42884

Kurhe Y, Mahesh R, Devadoss T, 2015. QCM-4, a 5-HT3 receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice. Biochem Biophys Res Commun, 456(1):74-79. https://doi.org/10.1016/j.bbrc.2014.11.036https://doi.org/10.1016/j.bbrc.2014.11.036

Kurhe Y, Mahesh R, Devadoss T, 2017. Novel 5-HT3 receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology, 234(7):1165-1179. https://doi.org/10.1007/s00213-017-4558-0https://doi.org/10.1007/s00213-017-4558-0

Lakhtakia T, Torous J, 2022. Current directions in digital interventions for mood and anxiety disorders. Curr Opin Psychiatry, 35(2):130-135. https://doi.org/10.1097/yco.0000000000000772https://doi.org/10.1097/yco.0000000000000772

Lecrubier Y, Puech AJ, Azcona A, et al., 1993. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology, 112:129-133. https://doi.org/10.1007/bf02247373https://doi.org/10.1007/bf02247373

Li HH, Liu YT, Gao XQ, et al., 2019. Neuroplastin 65 modulates anxiety- and depression-like behavior likely through adult hippocampal neurogenesis and central 5-HT activity. FEBS J, 286(17):3401-3415. https://doi.org/10.1111/febs.14865https://doi.org/10.1111/febs.14865

Lopes LT, Canto-de-Souza L, Baptista-de-Souza D, et al., 2022. The interplay between 5-HT2C and 5-HT3A receptors in the dorsal periaqueductal gray mediates anxiety-like behavior in mice. Behav Brain Res, 417:113588. https://doi.org/10.1016/j.bbr.2021.113588https://doi.org/10.1016/j.bbr.2021.113588

Lummis SCR, 2012. 5-HT3 receptors. J Biol Chem, 287(48):40239-40245. https://doi.org/10.1074/jbc.R112.406496https://doi.org/10.1074/jbc.R112.406496

Machu TK, 2011. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions. Pharmacol Ther, 130(3):338-347. https://doi.org/10.1016/j.pharmthera.2011.02.003https://doi.org/10.1016/j.pharmthera.2011.02.003

Maksay G, Bíró T, Bugovics G, 2005. Allosteric modulation of 5-HT3 serotonin receptors. Eur J Pharmacol, 514(1):17-24. https://doi.org/10.1016/j.ejphar.2005.03.019https://doi.org/10.1016/j.ejphar.2005.03.019

Marcinkiewcz CA, Mazzone CM, D'Agostino G, et al., 2016. Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature, 537(7618):97-101. https://doi.org/10.1038/nature19318https://doi.org/10.1038/nature19318

Martin KF, Hannon S, Phillips I, et al., 1992. Opposing roles for 5-HT1B and 5-HT3 receptors in the control of 5-HT release in rat hippocampus in vivo. Br J Pharmacol, 106(1):139-142. https://doi.org/10.1111/j.1476-5381.1992.tb14306.xhttps://doi.org/10.1111/j.1476-5381.1992.tb14306.x

Mascagni F, McDonald AJ, 2007. A novel subpopulation of 5-HT type 3A receptor subunit immunoreactive interneurons in the rat basolateral amygdala. Neuroscience, 144(3):1015-1024. https://doi.org/10.1016/j.neuroscience.2006.10.044https://doi.org/10.1016/j.neuroscience.2006.10.044

McCann UD, Morgan CM, Geraci M, et al., 1997. Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology, 17(6):360-369. https://doi.org/10.1016/s0893-133x(97)00085-7https://doi.org/10.1016/s0893-133x(97)00085-7

Mendelson SD, McEwen BS, 1991. Autoradiographic analyses of the effects of restraint-induced stress on 5-HT1A, 5-HT1C and 5-HT2 receptors in the dorsal hippocampus of male and female rats. Neuroendocrinology, 54(5):454-461. https://doi.org/10.1159/000125951https://doi.org/10.1159/000125951

Millan MJ, 2022. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol, 12:20451253221105128. https://doi.org/10.1177/20451253221105128https://doi.org/10.1177/20451253221105128

Motzkin JC, Philippi CL, Wolf RC, et al., 2015. Ventromedial prefrontal cortex is critical for the regulation of amygdala activity in humans. Biol Psychiatry, 77(3):276-284. https://doi.org/10.1016/j.biopsych.2014.02.014https://doi.org/10.1016/j.biopsych.2014.02.014

Murphy SE, Capitão LP, Giles SLC, et al., 2021. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry, 8(9):824-835. https://doi.org/10.1016/s2215-0366(21)00154-1https://doi.org/10.1016/s2215-0366(21)00154-1

Nowicki M, Tran S, Muraleetharan A, et al., 2014. Serotonin antagonists induce anxiolytic and anxiogenic-like behavior in zebrafish in a receptor-subtype dependent manner. Pharmacol Biochem Behav, 126:170-180. https://doi.org/10.1016/j.pbb.2014.09.022https://doi.org/10.1016/j.pbb.2014.09.022

Pallanti S, Bernardi S, Antonini S, et al., 2009. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs, 23(12):1047-1055. https://doi.org/10.2165/11530240-000000000-00000https://doi.org/10.2165/11530240-000000000-00000

Park J, Moghaddam B, 2017. Impact of anxiety on prefrontal cortex encoding of cognitive flexibility. Neuroscience, 345:193-202. https://doi.org/10.1016/j.neuroscience.2016.06.013https://doi.org/10.1016/j.neuroscience.2016.06.013

Riga MS, Sánchez C, Celada P, et al., 2016. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology, 108:73-81. https://doi.org/10.1016/j.neuropharm.2016.04.023https://doi.org/10.1016/j.neuropharm.2016.04.023

Rogan MT, Stäubli UV, Ledoux JE, 1997. Fear conditioning induces associative long-term potentiation in the amygdala. Nature, 390(6660):604-607. https://doi.org/10.1038/37601https://doi.org/10.1038/37601

Sah P, 2017. Fear, anxiety, and the amygdala. Neuron, 96(1):1-2. https://doi.org/10.1016/j.neuron.2017.09.013https://doi.org/10.1016/j.neuron.2017.09.013

Serata D, Kotzalidis GD, Rapinesi C, et al., 2015. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum Psychopharmacol, 30(2):70-84. https://doi.org/10.1002/hup.2461https://doi.org/10.1002/hup.2461

Sharafkhah M, Alamdar MA, Massoudifar A, et al., 2019. Comparing the efficacy of ondansetron and granisetron augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled study. Int Clin Psychopharmacol, 34(5):222-233. https://doi.org/10.1097/yic.0000000000000267https://doi.org/10.1097/yic.0000000000000267

Sharp T, Barnes NM, 2020. Central 5-HT receptors and their function; present and future. Neuropharmacology, 177:108155. https://doi.org/10.1016/j.neuropharm.2020.108155https://doi.org/10.1016/j.neuropharm.2020.108155

Ślifirski G, Król M, Turło J, 2021. 5-HT receptors and the development of new antidepressants. Int J Mol Sci, 22(16):9015. https://doi.org/10.3390/ijms22169015https://doi.org/10.3390/ijms22169015

Smith WT, Londborg PD, Blomgren SL, et al., 1999. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol, 19(2):125-131. https://doi.org/10.1097/00004714-199904000-00006https://doi.org/10.1097/00004714-199904000-00006

Solt K, Ruesch D, Forman SA, et al., 2007. Differential effects of serotonin and dopamine on human 5-HT3A receptor kinetics: interpretation within an allosteric kinetic model. J Neurosci, 27(48):13151-13160. https://doi.org/10.1523/jneurosci.3772-07.2007https://doi.org/10.1523/jneurosci.3772-07.2007

Soltani F, Sayyah M, Feizy F, et al., 2010. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol, 25(6):509-513. https://doi.org/10.1002/hup.1145https://doi.org/10.1002/hup.1145

Stefański R, Pałejko W, Bidzinski A, et al., 1993. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists. Neuropharmacology, 32(10):‍987-993. https://doi.org/10.1016/0028-3908(93)90063-9https://doi.org/10.1016/0028-3908(93)90063-9

Szeszko PR, Robinson D, Alvir JMJ, et al., 1999. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry, 56(10):913-919. https://doi.org/10.1001/archpsyc.56.10.913https://doi.org/10.1001/archpsyc.56.10.913

Taylor NE, Pei JZ, Zhang J, et al., 2019. The role of glutamatergic and dopaminergic neurons in the periaqueductal gray/dorsal raphe: separating analgesia and anxiety. eNeuro, 6(1):ENEURO.0018-18.2019. https://doi.org/10.1523/eneuro.0018-18.2019https://doi.org/10.1523/eneuro.0018-18.2019

Togao O, Yoshiura T, Nakao T, et al., 2010. Regional gray and white matter volume abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Psychiatry Res Neuroimaging, 184(1):29-37. https://doi.org/10.1016/j.pscychresns.2010.06.011https://doi.org/10.1016/j.pscychresns.2010.06.011

Tovote P, Fadok JP, Lüthi A, 2015. Neuronal circuits for fear and anxiety. Nat Rev Neurosci, 16(6):317-331. https://doi.org/10.1038/nrn3945https://doi.org/10.1038/nrn3945

Tovote P, Esposito MS, Botta P, et al., 2016. Midbrain circuits for defensive behaviour. Nature, 534(7606):206-212. https://doi.org/10.1038/nature17996https://doi.org/10.1038/nature17996

Tseilikman V, Akulov A, Shevelev O, et al., 2022. Paradoxical anxiety level reduction in animal chronic stress: a unique role of hippocampus neurobiology. Int J Mol Sci, 23(16):9151. https://doi.org/10.3390/ijms23169151https://doi.org/10.3390/ijms23169151

Turner TJ, Mokler DJ, Luebke JI, 2004. Calcium influx through presynaptic 5-HT3 receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies. Neuroscience, 129(3):703-718. https://doi.org/10.1016/j.neuroscience.2004.08.020https://doi.org/10.1016/j.neuroscience.2004.08.020

Urzedo-Rodrigues LS, Ferreira HS, Santana RC, et al., 2014. Blockade of 5-HT3 receptors in the septal area increases Fos expression in selected brain areas. Auton Neurosci, 181:55-68. https://doi.org/10.1016/j.autneu.2014.01.003https://doi.org/10.1016/j.autneu.2014.01.003

Uvnäs-Moberg K, Hillegaart V, Alster P, et al., 1996. Effects of 5-HT agonists, selective for different receptor subtypes, on oxytocin, CCK, gastrin and somatostatin plasma levels in the rat. Neuropharmacology, 35(11):1635-1640. https://doi.org/10.1016/s0028-3908(96)00078-0https://doi.org/10.1016/s0028-3908(96)00078-0

Vilela-Costa HH, Maraschin JC, Casarotto PC, et al., 2021. Role of 5-HT1A and 5-HT2C receptors of the dorsal periaqueductal gray in the anxiety- and panic-modulating effects of antidepressants in rats. Behav Brain Res, 404:113159. https://doi.org/10.1016/j.bbr.2021.113159https://doi.org/10.1016/j.bbr.2021.113159

Vu V, Conant-Norville D, 2021. Anxiety: recognition and treatment options. Psychiatr Clin North Am, 44(3):373-380. https://doi.org/10.1016/j.psc.2021.04.005https://doi.org/10.1016/j.psc.2021.04.005

Yakel JL, Jackson MB, 1988. 5-HT3 receptors mediate rapid responses in cultured hippocampus and a clonal cell line. Neuron, 1(7):615-621. https://doi.org/10.1016/0896-6273(88)90111-0https://doi.org/10.1016/0896-6273(88)90111-0

Yakel JL, Shao XM, Jackson MB, 1990. The selectivity of the channel coupled to the 5-HT3 receptor. Brain Res, 533(1):46-52. https://doi.org/10.1016/0006-8993(90)91793-ghttps://doi.org/10.1016/0006-8993(90)91793-g

Zhao HY, Lin Y, Chen SR, et al., 2018. 5-HT3 receptors: a potential therapeutic target for epilepsy. Curr Neuropharmacol, 16(1):29-36. https://doi.org/10.2174/1570159x15666170508170412https://doi.org/10.2174/1570159x15666170508170412

Zwanzger P, Domschke K, Bradwejn J, 2012. Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety, 29(9):762-774. https://doi.org/10.1002/da.21919https://doi.org/10.1002/da.21919